Kintara Therapeutics Stock Overview
Kintara Therapeutics (KTRA) started trading at $0.23. The stock’s 50-day average is $0.19, and the 200-day average is $0.20. It has a low of $0.08 and a high of $4.59 over the past year, with a market cap of $12.55 million and a negative PE ratio of -0.06.
About Kintara Therapeutics
Kintara Therapeutics is a clinical stage biopharmaceutical company focused on developing cancer treatments. Their main products include:
- VAL-083: A treatment for drug-resistant solid tumors, including some brain cancers.
- REM-001: A therapy for certain types of skin cancer and complications in dialysis patients.
Learn More
- Five stocks we prefer over Kintara Therapeutics
- Understanding ESG Stocks
- Goldman Sachs Earnings Insights
- Using the Russell 2000 Index
- AMD and AI: Growth Potential
- Interpreting Percentage Gainers
- Lithium Stocks to Watch
Sign Up for Kintara News: Enter your email below to get daily news updates and ratings for Kintara Therapeutics with MarketBeat.com’s FREE newsletter.
`
